Product Description
Abetimus [Abetimus sodium, LJP 394, Rentol, Riquent] is a synthetic Toleragen molecule consisting of four double-stranded oligodeoxyribonucleotides attached to nonimmunogenic polyethylene glycol, a proprietary carrier platform. Abetimus is an immunomodulating agent that induces tolerance in B cells directed against double-stranded DNA (dsDNA). It does this by cross-linking surface antibodies. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12749759/)
Mechanisms of Action: Immunosuppressive
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innoviva
Company Location: BURLINGAME CA 94010
Company CEO: Pavel Raifeld
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Lupus Erythematosus, Systemic|Lupus Nephritis|Kidney Diseases|Glomerulonephritis
Phase 2: Lupus Erythematosus, Systemic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ABETIMUS FOR LUPUS NEPHRITIS | P3 |
Terminated |
Lupus Erythematosus, Systemic|Kidney Diseases |
2011-08-16 |
|
| ASPEN | P3 |
Terminated |
Lupus Nephritis|Lupus Erythematosus, Systemic|Kidney Diseases |
2009-02-01 |
|
| 2006-000674-73 | P3 |
Active, not recruiting |
Kidney Diseases|Lupus Erythematosus, Systemic |
2008-06-02 |
|
| LJP 394-90-16 | P2 |
Withdrawn |
Lupus Erythematosus, Systemic |
None |